What Estée Lauder Companies (EL)'s Strong Quarter and XINÚ Investment Mean for Emerging Markets Strategy

• The Estée Lauder Companies Inc. recently reported stronger-than-expected first-quarter results for fiscal 2026, approved amendments to its Restated Certificate of Incorporation, added two new directors at its Annual Meeting, completed a US$1.02 billion follow-on equity offering, and announced a minority investment in Mexican luxury fragrance brand XINÚ through its New Incubation Ventures arm.
• This marked Estée Lauder's first investment in a Latin American brand and underscores the company's emphasis on expanding into emerging markets while supporting regional innovation in beauty and fragrance.
• We’ll explore how Estée Lauder’s investment in XINÚ and robust quarterly results strengthen its long-term emerging markets expansion narrative.

We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Estée Lauder Companies Investment Narrative Recap

To be a shareholder in Estée Lauder Companies, you need to believe in the continued expansion into high-growth emerging markets and the company's ability to revitalize its premium beauty brands through innovation. The recent strong first-quarter results reinforce the emerging market thesis, but short-term performance remains tightly tied to the recovery in travel retail, a channel still facing uncertainties and volatility, particularly in Asia. While the latest news signals good execution, it does not materially resolve the ongoing risk around global travel retail recovery.

The recent minority investment in XINÚ, Estée Lauder’s first foray into a Latin American beauty brand, is especially relevant as it supports their push for emerging market growth. By leveraging unique regional innovation and fragrance expertise, Estée Lauder is broadening its global footprint, offering incremental opportunities that could balance ongoing volatility in core travel retail and Western markets.

However, investors should also consider that, despite signs of strength, a full rebound in travel retail is far from assured and if this historic sales channel remains sluggish...

Read the full narrative on Estée Lauder Companies (it's free!)

Estée Lauder Companies' outlook projects $16.0 billion in revenue and $1.4 billion in earnings by 2028. This is based on analysts’ expectations of 3.9% annual revenue growth and an increase in earnings of $2.5 billion from the current -$1.1 billion.

Uncover how Estée Lauder Companies' forecasts yield a $101.87 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Ten fair value estimates from the Simply Wall St Community put Estée Lauder anywhere between US$60.66 and US$117.70 per share. With emerging markets targeted for double-digit growth, your view on near-term international momentum could shape how you interpret these wide-ranging opinions.

Explore 10 other fair value estimates on Estée Lauder Companies - why the stock might be worth 31% less than the current price!

Build Your Own Estée Lauder Companies Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Estée Lauder Companies research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Estée Lauder Companies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Estée Lauder Companies' overall financial health at a glance.

Want Some Alternatives?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com